{"id":"tolterodine-tartrate-er","safety":{"commonSideEffects":[{"rate":"35-40","effect":"Dry mouth"},{"rate":"5-7","effect":"Headache"},{"rate":"10-15","effect":"Constipation"},{"rate":"2-4","effect":"Dizziness"},{"rate":"1-2","effect":"Blurred vision"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tolterodine selectively antagonizes M2 and M3 muscarinic receptors in the detrusor muscle of the bladder. By blocking these receptors, it prevents acetylcholine-mediated bladder contractions, thereby increasing bladder capacity and reducing the frequency of micturition. The extended-release formulation provides sustained therapeutic effect over 24 hours.","oneSentence":"Tolterodine tartrate is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:09.903Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency"}]},"trialDetails":[{"nctId":"NCT05362292","phase":"PHASE4","title":"TReating Incontinence for Underlying Mental and Physical Health","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2022-10-04","conditions":"Urinary Incontinence, Urge, Urinary Incontinence, Overactive Bladder","enrollment":270},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":"Urinary Bladder, Overactive","enrollment":220},{"nctId":"NCT00688688","phase":"PHASE3","title":"Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2008-04-25","conditions":"Urinary Bladder, Overactive","enrollment":2792},{"nctId":"NCT01043666","phase":"PHASE3","title":"A Study of YM178 in Subjects With Symptoms of Overactive Bladder","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-12-21","conditions":"Urinary Bladder, Overactive","enrollment":1126},{"nctId":"NCT00649129","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT00649259","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-10","conditions":"Healthy","enrollment":39},{"nctId":"NCT00649727","phase":"PHASE1","title":"Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT03583372","phase":"PHASE3","title":"An Extension Study to Examine the Safety and Tolerability of a New Drug in Patients With Symptoms of Overactive Bladder (OAB).","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-06-14","conditions":"Overactive Bladder","enrollment":506},{"nctId":"NCT03492281","phase":"PHASE3","title":"A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Urovant Sciences GmbH","startDate":"2018-03-26","conditions":"Overactive Bladder","enrollment":1530},{"nctId":"NCT01302938","phase":"PHASE4","title":"Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder","status":"TERMINATED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2011-03","conditions":"Overactive Bladder","enrollment":18},{"nctId":"NCT00137397","phase":"PHASE4","title":"A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Urinary Incontinence","enrollment":80},{"nctId":"NCT00230789","phase":"PHASE4","title":"Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-10","conditions":"Urinary Incontinence","enrollment":417},{"nctId":"NCT00411437","phase":"PHASE4","title":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Memory, Cognition","enrollment":220},{"nctId":"NCT00147654","phase":"PHASE4","title":"Effect and Safety Of Detrol LA In Men With Overactive Bladder Symptoms With Or Without Bladder Outlet Obstruction","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-11","conditions":"Urinary Incontinence","enrollment":830},{"nctId":"NCT00645281","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2004-03","conditions":"Urinary Bladder, Overactive","enrollment":896},{"nctId":"NCT00143481","phase":"PHASE4","title":"Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2005-03","conditions":"Urinary Incontinence","enrollment":400},{"nctId":"NCT02138747","phase":"PHASE4","title":"A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2014-07-24","conditions":"Overactive Bladder (OAB)","enrollment":376},{"nctId":"NCT00730535","phase":"PHASE4","title":"Exploring Predictors of Symptoms Relapse After Discontinuation of Treatment in Overactive Bladder (OAB) Patients","status":"COMPLETED","sponsor":"KYU-SUNG LEE","startDate":"2006-08","conditions":"Overactive Bladder","enrollment":173},{"nctId":"NCT01741454","phase":"PHASE4","title":"Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2012-11","conditions":"Ureteral Obstruction","enrollment":181},{"nctId":"NCT01314872","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-03-31","conditions":"Urinary Bladder, Overactive","enrollment":1395},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":"Overactive Bladder, Overactive Urinary Bladder","enrollment":4},{"nctId":"NCT01302054","phase":"PHASE4","title":"A Clinical Study in Patients With Overactive Bladder With Leakage of Urine, to Find Out if the Medicine, Fesoterodine, Works in Those Patients Who Did Not Have Enough Response to the Medicine, Tolterodine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-05","conditions":"Urinary Bladder, Overactive","enrollment":990},{"nctId":"NCT01824420","phase":"PHASE4","title":"Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2013-03","conditions":"Overactive Bladder","enrollment":129},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36},{"nctId":"NCT00939120","phase":"PHASE4","title":"Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)","status":"COMPLETED","sponsor":"Siami, Paul F., M.D.","startDate":"2009-07","conditions":"Benign Prostatic Hyperplasia (BPH)","enrollment":46},{"nctId":"NCT00444925","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-04","conditions":"Overactive Bladder","enrollment":1712},{"nctId":"NCT00836381","phase":"PHASE4","title":"Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-02","conditions":"Overactive Bladder","enrollment":56},{"nctId":"NCT00703703","phase":"PHASE1","title":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Healthy","enrollment":117},{"nctId":"NCT00611026","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-02","conditions":"Overactive Bladder","enrollment":2417},{"nctId":"NCT00913315","phase":"NA","title":"Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis","status":"UNKNOWN","sponsor":"Chongqing Medical University","startDate":"2009-08","conditions":"Prostatitis","enrollment":30},{"nctId":"NCT00413790","phase":"PHASE4","title":"Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects","status":"COMPLETED","sponsor":"Novartis","startDate":"2006-11","conditions":"Healthy","enrollment":162}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"FLUSHING"},{"count":4,"reaction":"HEADACHE"},{"count":4,"reaction":"MUSCLE SPASMS"},{"count":4,"reaction":"URINARY INCONTINENCE"},{"count":3,"reaction":"DRUG INEFFECTIVE"},{"count":3,"reaction":"PRODUCT SUBSTITUTION ISSUE"},{"count":2,"reaction":"ABDOMINAL DISCOMFORT"},{"count":2,"reaction":"ALOPECIA"},{"count":2,"reaction":"BACK PAIN"},{"count":2,"reaction":"DEATH"}],"_approvalHistory":[],"publicationCount":130,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Detrol LA","Detrol (TM)","Detrusitol SR","Mariosea XL","Detrol LA™"],"phase":"marketed","status":"active","brandName":"Tolterodine Tartrate ER","genericName":"Tolterodine Tartrate ER","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tolterodine tartrate is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency. Used for Overactive bladder with symptoms of urge incontinence, urgency, and urinary frequency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}